• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
  • Menu

Sсientists at Moscow State University (MSU) a new treatment for sepsis

21.10.2019/in News /by Evgeniy Makarevich

Residents of the MSU research park developed a unique treatment for battling sepsis. It has successfully passed all clinical trials and is soon expected to be available for use in hospitals. The new treatment is based on polymer sorbents derived for the first time.

The press office of the university reported that scientists have developed a novel method for deriving porous polymers of irregular structure, aimed at removing blood lipopolysaccharides, which are responsible for development of this malignant process.

“The structure is the following: porous spherical microgranules of hypercrosslinked styrene-divinylbenzene copolymer is used as a matrix. The surface of pores of microgranules has a covalently immobilized synthetic ligand to “Lipid A”, which is the most conserved domain of bacterial lipopolysaccharide. The proposed materials were chosen on the basis of safety, resistance to sterilization, absence of emission of low molecular weight compounds. Such matrix is characterized by high hemocompatibility, optimal morphology of pores (high proportion of mesopores to volume), and easiness of surface modification. Meanwhile ligand is characterized by strength of a bond to a lipopolysaccharide molecule” commented one of the developers, Ivan Bessonov.

Thуmedical device is a cylindrical plastic case, filled with the sorbent, that has standard ports for connection with blood tubing sets (“adsorber”, “adsorption column”).

With the help of a specialized pump, patient’s blood under a low pressure is filtered through the sorbent, while the blood cells and large plasma proteins are able to pass through without retention. Meanwhile, lipopolysaccharides are bound to specialized segments of sorbent surface.

Thereby, the purified blood is returned to the circulatory system, while the toxic substances, tightly bound by the sorbent, are removed from the organism.

The press office stated that thus far the production of the polymer sorbent and other component parts for manufacturing the adsorbers has been initialized. Independent accredited laboratories have conducted technical and toxicity experiment both in vivo and in vitroto test for biocompatibility and absence of toxic substances in materials that are utilized, and the efficiency of lipopolysaccharide adsorption. Poszdravnadzor conducted an expertise of experiment protocols and technological documentation, and allowed their use in clinical practice, recognizing them as safe and corresponding to the claimed characteristics.

The effectiveness of this extracorporeal blood filtration (selective hemosorption of lipopolysaccharides) is further confirmed by its recent inclusion in a pricelist of compulsory medical insurance in Moscow, Saint-Petersburg, and other regions.

“This method has already become a part of an insured medicine system. The company’s upcoming plans include new developments in the area of sorption technologies for blood filtration, and new products based on it, as well as extended (post registration) clinical trials on already existing products” commented the press office.

Link: gmpnews.ru

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

1 + 3 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
Scientific journal The Lancet Respiratory Medicine published the results of... Jannsen and Nanolek are launching a project for localization of Darzalex®
Scroll to top